IGF-1 LR3: the complete guide
IGF-1 LR3 is a modified analog of insulin-like growth factor 1 with an extended half-life due to reduced IGF-binding-protein affinity. It is studied for anabolic and tissue-repair effects.
How IGF-1 LR3 works
IGF-1 LR3 binds the IGF-1 receptor, triggering cellular growth, proliferation, and differentiation pathways. The LR3 modification lets it circulate longer in its active form.
Typical IGF-1 LR3 dosage
Commonly reported research ranges: 20–80 mcg per injection, typically once daily.
Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.
How to reconstitute IGF-1 LR3
A widely used reconstitution for a 1 mg vial is 1 ml of bacteriostatic water. With a typical 40 mcg dose this works out to the unit count shown in the calculator below.
Half-life and administration frequency
Approximately 20–30 hours (substantially extended vs native IGF-1's ~10–20 minutes).
This half-life informs how often IGF-1 LR3 is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.
Reported side effects
- Hypoglycemia (dose-dependent — IGF-1 has insulin-like effects)
- Headache
- Injection-site reactions
- Possible cardiac or organ growth with chronic use
This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.
Common IGF-1 LR3 stacks
- Rarely stacked; dosing precision is critical
Storage and handling
Lyophilized refrigerated. Reconstituted: refrigerated, use within 14–28 days.
FDA and regulatory status
Not FDA approved. Research use only.
IGF-1 LR3 clinical trials and evidence
For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.
- IGF-1 clinical trial records — ClinicalTrials.gov
Track your IGF-1 LR3 protocol on iPhone
Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.
See the app →Frequently asked questions
What is IGF-1 LR3?
IGF-1 LR3 is a modified analog of insulin-like growth factor 1 with an extended half-life due to reduced IGF-binding-protein affinity. It is studied for anabolic and tissue-repair effects.
How does IGF-1 LR3 work?
IGF-1 LR3 binds the IGF-1 receptor, triggering cellular growth, proliferation, and differentiation pathways. The LR3 modification lets it circulate longer in its active form.
What is a typical IGF-1 LR3 dose?
Commonly reported ranges are 20–80 mcg per injection, typically once daily. This is research information, not a recommendation — dosing should be individualized under clinical guidance.
What is the half-life of IGF-1 LR3?
Approximately 20–30 hours (substantially extended vs native IGF-1's ~10–20 minutes). This influences how often it is administered.
How do you reconstitute IGF-1 LR3?
A common approach is to add 1 ml of bacteriostatic water to a 1 mg vial. Use the reconstitution calculator for exact unit counts.
What are the side effects of IGF-1 LR3?
Hypoglycemia (dose-dependent — IGF-1 has insulin-like effects); Headache; Injection-site reactions; Possible cardiac or organ growth with chronic use.
Is IGF-1 LR3 FDA approved?
Not FDA approved. Research use only.
Are there clinical trials for IGF-1 LR3?
Registered or published clinical-trial sources for IGF-1 LR3 are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.
References
- IGF-1 LR3 / Long R3 IGF-1 literature — PubMed. Primary studies on IGF-1 LR3 pharmacokinetics and activity vs native IGF-1
- Mecasermin (Increlex) — FDA Drugs@FDA — U.S. Food and Drug Administration. Approved rhIGF-1 reference for severe primary IGF-1 deficiency; LR3 is unapproved research variant
- IGF-1 clinical trial records — ClinicalTrials.gov. Human studies of IGF-1 and analogs
Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.